Poor Grade Aneurysmal Subarachnoid Hemorrhage Study Group (POGASH)

San Donato Group (GSD)

Status: Enrolling

Conditions: Subarachnoid Hemorrhage, Aneurysmal; Poor Grade Subarachnoid Hemorrhage

Treatments: Other: Standard management according to international/national guidelines

Study type: Observational

Funder types: Other

Identifiers

NCT04945603

POGASH

Details and patient eligibility

About

Multicentric registry study in order to define outcome, predictors, treatment effects and their modifiers in poor grade aneurysmal subarachnoid haemorrhage patients.

The search for outcome predictors is going to be subdivided into three main research areas:

1. outcome predictors in the emergency department (so called "early brain injury phase").
2. outcome predictors in the neurocritical care unit (so called "delayed brain injury phase").
3. Treatment strategies. Two other areas of research are identified: delayed cerebral ischemia (incidence, treatment, predictors, impact on outcome) and long term follow-up (recent evidences suggest that there may be a non-negligible proportion of poor grade subarachnoid hemorrhage patients who may benefit from substantial improvement at long-term (after 6-12 months of follow-up).

Enrollment: 800 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted to the emergency department because of aneurysmal subarachnoid hemorrhage of poor grade (IV-V) according to the WFNS classification.

Exclusion criteria

• Patients younger than 18 years old.
• Pregnant or breast-feeding patients.
• Aneurysmal subarachnoid hemorrhage due to trauma or vascular malformations other than cerebral aneurysms.

Trial design

800 participants in 1 patient group

Poor Grade Subarachnoid Hemorrhage

Description:

All patients (prospective and retrospective) included will have to present a subarachnoid hemorrhage defined poor grade according to the WFNS scale due to the rupture of an intracranial aneurysm. The patients are managed according to both most recent international guidelines on the specific disease (Stroke, May 2012) and according to national and institutional guidelines/protocols.

Treatment:

Other: Standard management according to international/national guidelines